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Peripheral nerve injuries are a frequent and disabling condition, which aﬀects 13 to 23 per 100.000 persons each year. Severe cases,
withstructuraldisruptionofthenerve,areassociatedwithpoorfunctionalrecovery.Theexperimentaltreatmentusingnervegrafts
to replace damaged or shortened axons is limited by technical diﬃculties, invasiveness, and mediocre results. Other therapeutic
choices include the adjunctive application of cultured Schwann cells and nerve conduits to guide axonal growth. The bone marrow
is a rich source of mesenchymal cells, which can be diﬀerentiated in vitro into Schwann cells and subsequently engrafted into
the damaged nerve. Alternatively, undiﬀerentiated bone marrow mesenchymal cells can be associated with nerve conduits and
afterward transplanted. Experimental studies provide evidence of functional, histological, and electromyographical improvement
following transplantation of bone-marrow-derived cells in animal models of peripheral nerve injury. This paper focuses on this
new therapeutic approach highlighting its direct translational and clinical utility in promoting regeneration of not only acute but
perhaps also chronic cases of peripheral nerve damage.
1.Introduction
The incidence of peripheral nerve injury in developed
countriesisestimatedbetween13and23per100.000persons
p e ry e a r[ 1–3]. Common reported causes include motor
vehicle accidents, lacerations with blades, glass or long bone
fractures, and sports injuries. These statistics may be under-
estimated since only traumatic injuries that reach the health
care system are included. Nontraumatic injuries, nerve
damage secondary to abdominal or pelvic surgeries, and
lesions that are not treated at a health facility remain to be
accounted[3].Asanexample,erectiledysfunctionsecondary
toprostatesurgeriesassociatedwithiatrogenictransectionof
erectile nerves occurs in approximately 35 to 86% of radical
prostatectomy surgeries [4, 5]. It is, however, in the war
scenario where the problem is more frequent. Blast injuries
predominate, often associated with complex soft tissue and
arterial wounds, most of which requiring limb amputation
[6].
Peripheral nerve injuries are classiﬁed according to their
severity, from type I, limited to demyelination, through type
V, which comprises disruption of all three layers of the nerve
endoneurium, perineurium, and epineurium. A sixth type
of injury has also been described, with diﬀerent degrees of
lesion within individual fascicules from the same nerve [6].
Recovery is inversely proportional to the severity of damage.
Endogenous repair initiates after injury but usually does not
sustain itself beyond 12 months [7] .I ft h en e r v ed o e sn o t
heal within this period of time, recovery is unlikely and
chronic pain and disability may persist. In serious injuries,
surgical intervention is usually necessary, aiming to align the
damaged axonal stumps, either through end-to-end sutures2 The Scientiﬁc World Journal
or by interposition of a nerve graft or even a scaﬀold for
axonal growth. Frequently, however, the procedure does not
suﬃce, and functional recovery is suboptimal [2, 6, 7].
Nerve repair is often disappointing and, despite best
eﬀorts, full functional recovery is seldom achieved, especially
regarding motor nerves [2]. The high incidence of peripheral
nerve damage, associated with poor reparative outcomes,
indicates the importance of the problem and the demand
for better regenerative therapies. In this context, the develop-
ment of new approaches, including cell-based therapies, may
improve outcomes and diminish the resulting disability of
aﬀected victims. Indeed, preclinical ongoing studies already
show positive results in models of erectile, facial, optic, and
sciatic nerve injuries [5, 8–11].
2.TheHealingProcessThat Follows
Nerve Injury
Peripheral nerve injury is followed by responses both from
segments of the axon, proximal, and distal to the damaged
area, and from the surrounding neural and nonneural cells.
As a ﬁrst endogenous reparative attempt, the neuronal cell
body increases in size, the Nissl bodies dissolve, and the
nucleus migrates peripherally, initiating a process of protein
synthesis [12]. The distal detached nerve undergoes intrinsic
fragmentation, as the ﬁrst stage of Wallerian degeneration.
Interestingly,distalnervedisintegrationdoesnotstartimme-
diately upon injury. In primates, axons remain intact during
days and can still transmit electric potentials when stimu-
lated [13, 14]. The following fragmentation of the axon is a
rapid event and seems to be mediated by activated intrinsic
proteases, including calpain and the ubiquitin-protease
system, and once started, it is completed within hours [15–
17]. Axonal and myelin debris is later phagocytosed by
local Schwann cells and recruited macrophages [18]. These
latter cells opportunely inﬁltrate through the broken blood-
nerve-barrier and myelin sheathing, attracted by speciﬁc
chemokines and cytokines [12, 19]. Neutralization of these
factors by speciﬁc antibodies delays demyelination and, in
consequence, axonal regeneration [12]. In fact, clearance
of myelin debris seems to be an important step for repair
since myelin contains inhibitors of axonal growth and may,
therefore, impair regeneration [20].
Schwann cells have a central role in nerve repair, not
only concerning Wallerian degeneration and remyelination
but also in promoting axonal growth. Experiments in which
these cells were either decreased in number or made non-
functional indicate a deﬁcient axonal regeneration, placing
the Schwann cell as an integral component of the regener-
ative process [21]. After injury, the Schwann cells become
activated,assumeamoreprimitive phenotype, and stimulate
axonal growth, with upregulation of growth-related genes,
including those that encode intrinsic neurotrophic factors
and key transcription factors [2, 8, 22]. Activated Schwann
cells produce collagen and laminin, creating a tunnel of
extracellularmatrix,andexpresscelladhesion moleculesand
receptors, including IL-1, N-cadherin, gamma integrins, and
the neural cell adhesion molecule (N-CAM) [2].
The mechanisms through which Schwann cells and the
damagedaxonscommunicatearepoorlyunderstood.Vrbova
et al. suggested that an interaction between neurotrans-
mitters and their upregulated receptors may be involved
and demonstrated that drugs that inhibit the binding of
acetylcholine to its receptors and the binding of ATP to P2Y
receptors decrease axonal regeneration [23]. Additionally,
HNK-1 glycan, which is a marker of regeneration mediated
by Schwann cells in motor nerves, was decreased in the
animals with neurotransmitter blockage [23, 24]. Goethals
et al. describe Toll-like receptors as mediators of damage
recognition between Schwann cells and axons [25]. Schwann
cells constitutively express Toll-like receptors and, therefore,
play a sentinel role. Toll-like receptor ligands released by
degenerating axons stimulate Schwann and immune cells to
clear myelin and start the reparative process.
The resulting supportive environment yields Schwann
cell proliferation, formation of B¨ ungner bands, and, ﬁnally,
axonal sprouting [2, 26, 27]. This sprouting occurs at a
rate of 1 to 4mm per day, with progressive myelination
of the ﬁbers by the neighboring Schwann cells. The ﬁnal
repaired nerve usually presents thinner myelin sheets with
shorter nodal lengths, less functional than the original nerve
[28]. Time is an important factor aﬀecting nerve repair. The
supportive response mediated by neural and nonneural cells
is more pronounced in the few months that follow nerve
injury [6, 7, 28, 29]. When surgical intervention is delayed,
the chronically denervated Schwann cells begin spontaneous
apoptosis and repair becomes less probable. Recently, Gor-
don et al. demonstrated that although denervation of the
distal stump is the main determinant, the denervated muscle
also negatively impacts functional outcome [29]. Therefore,
attempts to enhance nerve regeneration should be initiated
as early as possible.
3. Interventionsto Improve
Peripheral Nerve Repair
Nerve repair requires a complex interaction of a scaﬀold for
axonal proliferation, supportive cells such as the Schwann
cells, growth factors, and extracellular matrix [2, 30]. There-
fore, alignment of the nerve stumps stands as one of the ﬁrst
interventions after peripheral nerve injury. When end-to-
end suture of the nerve is not possible, the interposition of
a nerve conduit becomes necessary. Autologous grafts are
often harvested from the sural or sensory nerves; however,
sometimes there are limitations such as tissue availabil-
ity, size incompatibilities, and deformities. Nevertheless,
autologous nerve grafts are considered the gold standard
for repairing peripheral nerve gaps [31]. Less frequently,
allografts can be used, with the disadvantages of requiring
immunosuppression and of producing worse outcomes than
autografts.
More recently, tissue engineering has provided nerve
conduits, which function as guides for axonal growth.
Depending on the materials used for their construction, they
can be classiﬁed as natural, when based on laminin, collagen
or even vessels and decellularized nerves, or artiﬁcial, usually
made of polymers. Artiﬁcial, nonbiodegradable scaﬀoldsThe Scientiﬁc World Journal 3
aid nerve growth and provide beneﬁcial results. However,
these conduits may lead to chronic inﬂammation and tissue
compression and therefore must be surgically removed once
neural healing has been concluded. To avoid the hurdles of
a second surgery on the injury site, biodegradable scaﬀolds
are preferred. Table 1 includes some examples of experi-
mentalstudiesthatusedbiodegradablescaﬀolds.Concerning
humans, recently ˚ Aberg et al. suggested that wrapping-
around injured wrist/forearm nerves with a resorbable
poly[(R)-3-hydroxybutyrate] (PHB) implant, promoted sig-
niﬁcant sensory and motor improvements when compared
to end-to-end epineural suture alone [32]. Importantly, no
adverse eﬀects were associated with the procedure, therefore
considered safe.
Sensory nerves usually have better outcomes than motor
nerves, after reconstructive interventions [48]. However,
sensory repair is only warranted in areas of critical sensation,
while motor nerves are usually indispensable. Motor nerve
repair is mostly worth when the site of injury is close to the
end organ because if the length to be repaired is too long,
by the time reinnervation is achieved, the end-organ may
be already unresponsive. In these cases, nerve transfer proce-
dures, if available, may be attractive alternatives.
The major limitation for use of nerve conduits is the
low rate of axonal growth, which may not yield full repair
within the available time. Studies have shown that the
conduits are eﬀective in promoting repair of nerve gaps
measuring up to 3cm, while nerve autografts are required
for bridging of larger distances [49, 50]. As an attempt to
apply nerve guides for axonal growth in larger nerve injuries,
Kokai et al. used polymer tube-like scaﬀolds associated with
microparticlesofGDNF,aimingtoincreasetherateofaxonal
growth and improve the success of functional restoration
[40]. Endogenous Schwann cells have been shown to be
attracted by the GDNF particles, increasing the rate of nerve
regeneration. Similarly, Liu et al. observed higher nerve
repair rates in rats with peripheral nerve injury treated with
biodegradable conduits associated with nerve growth factor
(NGF) [51].
Schwann cells are also potentiated by associations with
other cell types or by bioengineering. Olfactory ensheathing
cells (OECs) successfully repair peripheral nerve injuries and
with less eﬃciency central nervous system axonal lesions
[52]. However, Verd´ u et al. and You et al. demonstrated
that the association of Schwann cells and OECs promotes
better myelination and functional repair to injured sciatic
axons than either cell type alone [53, 54]. Another stud-
ied approach involves genetic engineering, inducing the
Schwann cells to express cell adhesion molecules, therefore
improving their regenerative capacity. Increasing the rate
of axonal repair may enhance the chances of successful
functional recovery since the outcomes are in most cases
time dependent. Lavdas et al. have investigated the eﬀects
of Schwann cells genetically modiﬁed to overexpress cell
adhesion molecules, mostly the polysialylated form of neural
celladhesionmoleculeNCAM,onnervoussystemrepair[55,
56].Itishypothesizedthattheseadhesionmoleculesimprove
transplanted cell migration, increasing their interaction with
the host environment, therefore promoting more eﬃcient
functional integration. Additionally, cell adhesion molecules
also stimulate axonal growth and remyelination, increasing
the rate of renervation [57, 58].
4.Sourcesof SchwannCellsand
ExperimentalStudies
Schwann cells are embryologically derived from the neural
crest [59, 60]. Some neural crest pluripotent and stem cells
(NCSCs) persist in adult specimens in sites of gliogenesis
such as the sciatic nerve and dorsal root ganglia. Migration,
proliferation, expression of growth factors, and remyelina-
tion capacity are listed features associated with Schwann
cells, indicating their stem cell behavior [61, 62]. Attempts
to use Schwann cells expanded in culture for neural repair
have been described in the literature for over two decades
[62]. Recently, Hood et al. used artiﬁcial tubes ﬁlled with
autologous Schwann cells to replace gaps between sciatic
nerve stumps of rats, with reported functional recovery
[63].
The combination of axonal scaﬀolds and transplanted
Schwann cells provides adequate support for peripheral
nerve repair and has been investigated in the experimental
setting as a strategy to circumvent the limitations of surgical
repair [34, 37, 45]. The cells can be delivered inside a hollow
tube, seeded in a hydrogel and subsequently ﬁlled into the
lumen of the conduit, or placed inside a conduit containing
a supportive structure [30]. Most studies use the ﬁrst type
of delivery, but it may be associated with substantial cell
loss [38, 43, 46, 63]. Improved outcomes have been obtained
using the second [34, 37] and third [45] approaches, but
these are more technically complicated and costly. Although
successful, these procedures are limited by the high number
of cells required for each intervention, potential injury to the
donor nerve, and ﬁbroblast contamination of the cultures
[64]. Therefore, alternative sources of supportive cells have
been researched.
The bone marrow may be an attractive source despite
the large number of available tissues from which Schwann
cells can be obtained. Bone marrow mesenchymal cells have
been studied for years in the context of in vitro expansion
and transplantation [65]. Their ease of access, abundance,
and safety are important attributes, especially concerning
clinical application. Mesenchymal stromal cells (MSCs) or
bone marrow stromal cells are multipotent somatic stem
cells, from a nonhematopoietic precursor anchored in bone
marrow that can diﬀerentiate in mesodermal cell linages,
neural phenotypes, and also into Schwann-like cells [47,
66] .W h e nM S C sa r ep l a c e di na na p p r o p r i a t ec u l t u r e
media, they transdiﬀerentiate into a glial cell phenotype
that expresses S100, GFAP, and p75 [67, 68]. In vitro
diﬀerentiated cells show promising results when associated
withartiﬁcialconduitsandacellulargrafts,promotingaxonal
and functional recovery [39, 41, 67].
Table 1 describes several preclinical studies that evaluate
the reparative eﬀects of diﬀerent kinds of cell therapy upon
peripheral nerve damage. Besides nervous tissue and bone
marrow, other alternative sources of cell are investigated,
such as the adipose tissue and skin. The skin dermis is4 The Scientiﬁc World Journal
Table 1: Preclinical studies evaluating cell therapy for peripheral nerve repair∗.
Study Injury type/animal model Cellular type/factor Major ﬁndings
McKenzie et al. [33]
Sciatic nerve crush injury
in myelin-deﬁcient mice
Skin-derived precursors diﬀerentiated
into Schwann cells
Remyelination and functional
recovery
Udina et al. [34]
Sciatic nerve injury in mice
(0.6cm gap)
Collagen guides seeded with allogeneic
Schwann cells plus FK-506
Successful regeneration and
functional recovery
Negishi et al. [11]
Optic nerve injury in rats
(transection)
Extracellular matrix Schwann cells and
neurotrophins
Axonal regeneration of retinal
ganglion cells
Reid et al. [35]
Sciatic nerve injury in rats
(1.0cm gap) Adipose-derived stem cells Dorsal root ganglia protection
from apoptosis
di Summa et al. [36]
Sciatic nerve injury in rats
(1.0cm gap)
Nerve ﬁbrin conduits seeded with
adipose-derived stem cells Enhanced peripheral nerve repair
Evans et al. [37]
Sciatic nerve injury in rats
(1.2cm gap)
Biosynthetic conduits seeded with
Schwann cells Increased nerve regeneration
Koshimune et al. [38]
Sciatic nerve injury in rats
(1.2cm gap)
Bioabsorbable Schwann cell-coated
conduits Axonal regeneration
Ladak et al. [39]
Sciatic nerve injury in rats
(1.2cm gap)
Bone marrow MSCs diﬀerentiated into
Schwann-like cells seeded in collagen
conduits
Regeneration of sciatic
motoneuron
Kokai et al. [40]
Sciatic nerve injury in rats
(1.5cm gap)
Scaﬀolds containing GDNF
microparticles
Increased rate of nerve
regeneration; migration and
proliferation of Schwann cells
Dezawa et al. [41]
Sciatic nerve injury in rats
(1.5cm gap)
Bone marrow MSCs diﬀerentiated into
Schwann-like cells suspended in Matrigel
injected into hollow ﬁbers
Successful nerve regeneration
and myelination
Marchesi et al. [42]
Sciatic nerve injury in rats
(1.6cm gap) Guides ﬁlled with skin-derived stem cells Functional recovery and
myelination
Ansselin et al. [43]
Sciatic nerve injury in rats
(1.8cm gap)
Nerve guides ﬁlled with syngeneic
Schwann cells
Successful nerve regeneration
conditional to number of cells
implanted
May et al. [5]
Cavernous nerves sections
in rats (0.5cm gap)
Silicon tubes seeded with
GDNF-transduced Schwann cells
Increased recovery of erectile
function
Sun et al. [44]
Facial nerve injury in rats
(0.8cm gap)
Decellularized artery allografts with
autologous adipose-derived stem cells
Nerve repair and functional
recovery
Wang et al. [10]
Facial nerve injury in
rabbits (1.0cm gap)
Autologous vein graft ﬁlled with
autologous MSCs diﬀerentiated into
Schwann cells
Improvement of functional
recovery and upregulated myelin
mRNA
Cheng and Chen [45]
Sciatic nerve injury in
rabbits (2.0cm gap)
Polyglactin scaﬀolds seeded with
Schwann cells and coated with
biomembranes
Successful nerve regeneration
Zhang et al. [46]
Tibial nerve injury in
rabbits (4.0cm gap)
Autogenous venous graft ﬁlled with
Schwann cells
Successful nerve regeneration
and electromyographic
improvementThe Scientiﬁc World Journal 5
Table 1: Continued.
Study Injury type/animal model Cellular type/factor Major ﬁndings
Wakao et al. [47]
Non-human primates
median nerve injury
(2.0cm gap)
Collagen guides seeded with bone
marrow MSC-derived Schwann cells
Functional, histological, and
electromyographical recovery
Hu et al. [31] Non-human primates ulnar
nerve injury (4.0cm gap)
Acellular allogeneic nerve grafts with
autologous MSCs
Structural and functional
peripheral nerve repair
∗The studies are grouped by animal model, nerve type, and injury size, starting with mice, followed by rats, rabbits, and nonhuman primates. The table does
not list all the available studies but describes the main publications.
another investigated cell source and contains neural crest-
related precursors skin precursor cells SKPCs that can dif-
ferentiate into neural crest cell types in vitro, including those
with characteristics of peripheral neurons and Schwann cells
[33, 69]. Also, the bulge area of the hair and whisker follicles
harbors NCSC that can diﬀerentiate into Schwann-like
cells, becoming an accessible source of cells for transplant.
B o t hN C S Ca n dS K P Ch a v eb e e nu s e di ne x p e r i m e n t so f
peripheral nerve and spinal cord injuries with functional
improvement after transplantation [33, 42, 70, 71].
Regarding the adipose tissue, Reid et al. showed that
diﬀerentiated adipose-derived Schwann cells expressed a
range of intrinsic neurotrophic factors [35, 72]. They also
demonstrated that the incorporation of either adipocyte-
derived or nerve-derived Schwann cells into the repair site
signiﬁcantly increased the expression of anti-apoptotic m-
RNA of Bcl-2 and decreased proapoptotic m-RNA Bax and
caspase-3 in dorsal root ganglia, therefore promoting a
neuroprotective eﬀect[72]. In a comparative study for sciatic
nerve repair using a ﬁbrin conduit seeded with diﬀerent cell
populations, primary Schwann cells showed better results
over adipose and bone-marrow-derived mesenchymal stem
cells; however, the two last cell types still showed better
axonal regeneration than the control, nontreated group [36].
Adipose-tissue-derived Schwann cells have also been used in
experimentalmodels of facialpalsywithpositive results[44].
Sun et al. published a study in rats with lesions of facial nerve
that presented functional and electrophysiological recovery
of nerve injuries measuring 0.8cm.
Neural stem cells directly transplanted in the site of
peripheral nerve injury diﬀerentiate into Schwann-like cells,
secrete neural growth factors, and improve nerve regenera-
tion [8]. In addition, these cells can enhance compatibility
between transplanted and surrounding tissue, decreasing
the necessity of immunosuppressive agents. Moreover, the
coculture and cotransplantation of neural stem cells with
Schwann cells increase the diﬀerentiation of neural stem cells
into neurons and improve functional recovery in models of
spinal cord injury [73].
Recently, Wakao et al. used collagen nerve conduits ﬁlled
with autologous bone marrow MSC diﬀerentiated in vitro
into Schwann cells to promote repair of median nerve
injuries in monkeys [47]( T a b l e1). Successful outcomes were
reported, with functional, histological, and electromyo-
graphical improvements. Interestingly, Hu et al. demon-
strated that allogeneic acellular nerves ﬁlled with autolo-
gous,butnondiﬀerentiated,bone-marrow-derivedMSCalso
promoted functional recovery when placed in ulnar nerve
gaps of nonhuman primates [31]. The success rates were
comparable to those from nerve autografts and autologous
Schwann-cell-ﬁlled acellular nerves and better than controls,
which received the acellular nerves not ﬁlled with cells.
The similar outcomes of both studies raise the hypothesis
that prediﬀerentiation of MSC into Schwann cells may
not be necessary to achieve repair. Moreover, a previous
study had demonstrated that allogeneic Schwann cells locally
transplanted into a rat model of spinal cord injury induced
the inﬁltration of endogenous Schwann cells into the
damaged site [74]. Although the observation should not be
transposed to peripheral nerve injury, it suggests a paracrine,
rather than replacement therapeutic eﬀect. On the other
hand, Sun et al. recently published a study in rats with
facial nerve injuries treated with decellularized allogeneic
arteries ﬁlled with adipose-tissue-derived Schwann cells,
where transplanted cells survived in the graft over 8 weeks
[75]. Studies establishing the exact fate of labeled Schwann
cells are still needed. Although in vitro studies demonstrate
diﬀerentiation of the MSC into diﬀerent cell types, mainly of
mesodermal lineage, in vivo studies fail to show convincing
evidence of such event. It is possible that the MSCs promote
healing eﬀects mostly through paracrine action, inducing
recruitment of neighboring host cells, modulation of local
and perhaps systemic immune response, and improving cell
survival, than through direct cell diﬀerentiation.
5. ClinicalTrialof Nerve Graftsand Scaffolds
Clinical applications of cell therapy for peripheral nerve
repair are rare. A clinical trial conducted by the University
of Stanford used scaﬀolding tubes ﬁlled with longitudinal
collagen ﬁbers as guides for axonal growth [76]. Such tubes
were occupied by autologous cultured Schwann cells and
served as a replacement for nerve autografts, aiming to
repair short and long gaps. Results were partially reported,
including cell harvesting, expansion in culture, and assembly
of cells and nerve conduits, but clinical outcomes have not
yet been published [76]. Another proposed study (Clini-
calTrials.gov identiﬁer: NCT00953277), currently recruiting
patients, intends to evaluate the eﬀects of a commercial
nervescaﬀoldonerectilefunctionandcontinenceaftervideo
laparoscopic radical prostate excision [77]. The surgery is
associated with high incidence of erectile nerve transection
anddirectlyaﬀectspostoperativequalityoflifeofthepatients
[4, 5]. According to advertisements, the product is derived6 The Scientiﬁc World Journal
from human decellularized nerves and may stand as an
“oﬀ the shelf” product, viable for three years in frozen
storage [78]. The same company sponsors a comparative
study between the above-mentioned commercial human-
derived nerve scaﬀold and synthetic or biosynthetic hollow
tubes to repair peripheral nerve gaps in the hand (Clinical-
Trials.gov identiﬁer: NCT00948025) [79]. Although not yet
approached by these last two studies, cell application to the
nerve conduits may be attempted in the future.
6. PracticalIssues
Cell-based therapy associated with scaﬀolds is a promising
branch of regenerative medicine. Nerve injuries are a fre-
quent and disabling condition, usually aﬀecting young and
productive subjects, which may beneﬁt from such proce-
dures. The idea of using nerve conduits ﬁlled with bone-
marrow mesenchymal cells may be an attractive alternative
to more aggressive therapies. If successful, the treatment
may lead to functional improvement, avoiding the hurdles
of additional surgeries and use of immunosuppressive drugs.
A hypothetical scenario would be a patient with a traumatic
limb injury, including extensive and severe damage of a
motor nerve, resulting in acute disability. There would be a
nerve gap,precluding anyattempt of directnerve suture.The
use of a nerve conduit ﬁlled with allogeneic bone marrow-
derived MSCs would be proposed, as an alternative to the
standard autologous nerve graft implant. The acute nature
of the condition would require a readily available source
of cells, and since MSCs are immunoprivileged, indicating
poor alloimmune response and therefore delayed rejection,
allogeneic sources would be ideal. The cells would be already
isolated from donated bone marrow, expanded in culture
without further manipulation, tested for safety and quality,
cryopreserved and ready for clinical use. The necessary
amount of cells would then be thawed and inserted into
biodegradable nerve conduits, readily implanted between
nerve stumps during microsurgery. The therapy would
require no immunosuppression and sequential functional
and electromyographical evaluations would determine the
outcomes. Expected results would be axonal repair, remyeli-
nation, and progressive functional improvement, either
through diﬀerentiation of the transplanted into Schwann-
like cells or, most probably, through paracrine eﬀects of
the bone-marrow-derived MSCs on the proximal axonal
stump and remaining endogenous Schwann cells, stimulat-
ing regeneration (see Figure 1).
Cell banking is a developing resource for repair in
degenerative, inﬂammatory, and traumatic disorders. The
rising number of cell banking companies reﬂects the increas-
ing number of emergent therapeutic applications for cells
derived from the bone marrow, cord blood, and multi-
ple other tissues. Although the regenerative potential and
the properties of the cells change slightly from tissue to
tissue, the bone marrow still stands as a preferred source
of hematopoietic and mesenchymal cells, due safety, easy
harvesting, and previous clinical experience [65]. Allogeneic
cell banking seems more logical as an “oﬀ the shelf” product,
however investments in autologous cell preservation may
be also interesting, as an insurance against future illnesses.
Transplanted autologous MSCs may persist in the injury
site longer because of absent immune rejection, therefore
promoting long-lasting eﬀects.
TheapplicationofMSCsisassociatedwithsomehurdles.
The most obvious is cell viability after thawing and insertion
into the conduit. Orthopedic reconstructive surgeries are
often long-lasting and the exposure of the cells to a hostile
environment may jeopardize their survival. Therefore, one
approach would be to leave cell implantation as a ﬁnal
step of the surgery, immediately followed by closure of the
incision. Perhaps, performance of the surgery by a skilled
surgeon may be critical. Additional aggressions to the cells
would be the presence of infection or any situation leading
to an acidic or hypooxygenated environment. Therefore,
these conditions must be strictly controlled before cell
transplantation. A second concern is that MSCs may lead
to abnormal, nonlinear nerve growth, due to aberrant
stimulation of the sprouting axonal buds. Although the
problem has been observed in nerves stimulated with growth
factors [80], such behavior is not expected following MSC
grafts. This potential problem may be prevented through
use of good quality conduits, possibly containing an internal
supportive structure, aiming to guide newly formed axons in
the direction of the distal nerve stump. Third, the therapy
may promote cell diﬀerentiation toward a nonexpected cell
type. Malignancy is not reported as a usual consequence
of MSC administrations, but it is possible that due to the
local host conditions the cells diﬀerentiate into nonneural
cell types. Another concern that may be discussed is the
functional integration of the transplanted cells into the
injured nerve [81], although repair of peripheral nerve is
usually more successful than central nervous system injuries.
Finally, some donor conditions may interfere with MSC
cultures, such as advanced age, smoking, and diabetes [82,
83].Inthesecases,autologoususemaynotbethebestchoice.
In summary, despite the reported therapeutic beneﬁts of
MSC therapy in experimental models of peripheral nerve
injury, there remain translational hurdles that still need to
be addressed before the realization of large clinical trials
for this treatment. In the future, this form of cell therapy
may aggregate more complex features, such as addition of
trophic factors within the conduits, manipulation of the
cells for expression of neurotrophic factors or even adhesion
molecules. On the other hand, the procedure may remain
simple and enable the investigation of therapeutic pathways,
perhaps unveiling a speciﬁc substance that would be thera-
peutically active, therefore sparing the use of cells.
7. Conclusions
Spontaneous peripheral nerve repair is disappointing even
aftermicrosurgicalintervention,especiallyconcerningsevere
injuries. Resulting chronic pain and disability aﬀects victims
of all ages, including those in economically active phase
of life [3]. The available treatment using nerve grafts is
very limited and invasive, and new therapeutic options are
required. Schwann cell cultures have demonstrated favorable
results in the experimental setting; however, the ideal sourceThe Scientiﬁc World Journal 7
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Figure 1: Stem cell with scaﬀold support in peripheral nerve injury. (a) Nerve injury with stem cell transplantation shows limited
remyelination and axonal growth between the proximal and distal stumps. (b) Nerve injury with scaﬀolding devices can be fabricated to
secrete neurotrophic factors aiming to enhance the regenerative process, but still the outcome results in limited remyelination and axonal
growth between the proximal and distal stumps. (c) The combined use of stem cells and scaﬀolding promotes best results, allowing an
improved substrate for cell-to-cell contact and increased concentrations of released neurotrophic factors. Additionally, transplanted stem
cells may stimulate endogenous Schwann cells to proliferate at a higher rate, thus enhancing remyelination and axonal growth following
peripheral nerve damage.
of cells has not yet been established. Bone-marrow-derived
mesenchymal cells present encouraging results and may
become the ideal cell for clinical translation. These cells have
been exhaustively investigated during the last two decades
and approved for use in numerous clinical trials, especially
aiming at immunomodulation and tissue repair [84].
The bulk of preclinical studies oﬀer many advantages of
MSC therapy for peripheral nerve injury. The ﬁrst advantage
of bone-marrow-derived MSC is the uncomplicated and
minimally invasive harvesting of the cells through aspiration
of reduced volume of bone marrow from the iliac crest.
Second, in vitro cultures are in most cases simple, with
adequate proliferation rates and high cell viability [65, 66].
Large number of cells can be obtained within a few weeks.
Third, these cells are considered safe, and not associated with
malignancy, uncontrolled proliferation or graft-versus-host
disease. Fourth, MSCs are immunologically privileged and,
thus, even allogeneic cells are not readily rejected by the host.
Although some immune response is elicited through time,
the cells survive long enough for therapeutic eﬀectiveness
without need of immunosuppressant drugs [84]. Fifth,
in vitro diﬀerentiation into Schwann cells is possible and
already described by several authors [30, 37, 63]. Finally,
MSCs secrete trophic factors, stimulating neuron regenera-
tion,and,possibly,contributingtoasupportiveenvironment
[85].
Cultured cells, combined with adjunctive treatments
such as axonal growth guides, may be a feasible approach
for future clinical studies (see Figure 1). Severe injuries in
which nerve grafts are not available may beneﬁt from this
strategy that may provide an extracellular substrate for the
transplanted cells and spared host cells allowing a bridge
for cellular integration and/or a cellular and molecular
pathway for improved paracrine eﬀects. Moreover, studies
investigating the eﬀects of these cells over situations of
delayedsurgicalinterventionandchronicaxonaldenervation
have not been reported. The neurotropic eﬀect of these
cells, combined with a favorable eﬀect over the surrounding
environment, may prolong the time window for axonal
regeneration and, perhaps, improve the rates of functional
restoration even in chronic cases.
Acknowledgments
C. V. Borlongan is supported by NIH NINDS
1R01NS071956-01, James and Esther King Foundation8 The Scientiﬁc World Journal
for Biomedical Research Program, SanBio Inc., Celgene
Cellular Therapeutics, KMPHC, and NeuralStem Inc.
References
[1] M. Asplund, M. Nilsson, A. Jacobsson, and H. von Holst,
“Incidenceoftraumaticperipheralnerveinjuriesandamputa-
tions in Sweden between 1998 and 2006,” Neuroepidemiology,
vol. 32, no. 3, pp. 217–228, 2009.
[2] G. R. D. Evans, “Peripheral nerve injury: a review and
approach to tissue engineered constructs,” The Anatomical
Record, vol. 263, no. 4, pp. 396–404, 2001.
[3] C. A. Taylor, D. Braza, J. B. Rice, and T. Dillingham, “The
incidence of peripheral nerve injury in extremity trauma,”
American Journal of Physical Medicine & Rehabilitation, vol.
87, no. 5, pp. 381–385, 2008.
[4] S. D. Kundu, K. A. Roehl, S. E. Eggener, J. A. Antenor, M. Han,
andW.J.Catalona,“Potency, continenceandcomplicationsin
3,477 consecutive radical retropubic prostatectomies,” Journal
of Urology, vol. 172, no. 6 I, pp. 2227–2231, 2004.
[5] F. May, K. Matiasek, M. Vroemen et al., “GDNF-transduced
schwann cell grafts enhance regeneration of erectile nerves,”
European Urology, vol. 54, no. 5, pp. 1179–1187, 2008.
[6] W. W. Campbell, “Evaluation and management of peripheral
nerve injury,” Clinical Neurophysiology, vol. 119, no. 9, pp.
1951–1965, 2008.
[7] O. A. Sulaiman and T. Gordon, “Eﬀects of short- and
long-term Schwann cell denervation on peripheral nerve
regeneration, myelination, and size,” GLIA,v o l .3 2 ,n o .3 ,p p .
234–246, 2000.
[8] M. M. Dong and T. H. Yi, “Stem cell and peripheral nerve
injury and repair,” Facial Plastic Surgery,v o l .2 6 ,n o .5 ,p p .
421–427, 2010.
[ 9 ]L .N .Z h o u ,J .W .Z h a n g ,J .C .W a n g ,W .L .L e i ,X .L .L i u ,a n d
L. H. Zhou, “Bone marrow stromal and Schwann cells from
adult rats can interact synergistically to aid in peripheral nerve
repair even without intercellular contact in vitro,” Cellular
Physiology and Biochemistry, vol. 27, pp. 565–574, 2011.
[10] X. Wang, E. Luo, Y. Li, and J. Hu, “Schwann-like mesenchymal
stem cells within vein graft facilitate facial nerve regeneration
andremyelination,”BrainResearch,vol.1383,pp.71–80,2011.
[11] H. Negishi, M. Dezawa, T. Oshitari, and E. Adachi-Usami,
“Optic nerve regeneration within artiﬁcial Schwann cell graft
in the adult rat,” Brain Research Bulletin,v o l .5 5 ,n o .3 ,p p .
409–419, 2001.
[12] F. E. Perrin, S. Lacroix, M. Avil´ es-Trieueros, and S.
David, “Involvement of monocyte chemoattractant protein-
1, macrophage inﬂammatory protein-1α and interleukin-1β
Wallerian degeneration,” Brain, vol. 128, no. 4, pp. 854–866,
2005.
[13] V. Chaudhry, J. D. Glass, and J. W. Griﬃn, “Wallerian degen-
eration in peripheral nerve disease,” Neurologic clinics, vol. 10,
no. 3, pp. 613–627, 1992.
[14] R. W. Gilliatt and R. J. Hjorth, “Nerve conduction during
Wallerian degeneration in the baloon,” Journal of Neurology
Neurosurgery and Psychiatry, vol. 35, no. 3, pp. 335–341, 1972.
[15] E. Touma, S. Kato, K. Fukui, and T. Koike, “Calpain-mediated
cleavage of collapsin response mediator protein(CRMP)-2
during neurite degeneration in mice,” European Journal of
Neuroscience, vol. 26, no. 12, pp. 3368–3381, 2007.
[16] Q. Zhai, J. Wang, A. Kim et al., “Involvement of the
ubiquitin-proteasome system in the early stages of Wallerian
degeneration,” Neuron, vol. 39, no. 2, pp. 217–225, 2003.
[17] B. Beirowski, R. Adalbert, D. Wagner et al., “The progressive
nature of Wallerian degeneration in wild-type and slow Wal-
lerian degeneration (WldS) nerves,” BMC Neuroscience, vol. 6,
article 6, 2005.
[18] M. P. Coleman and M. R. Freeman, “Wallerian degeneration,
WldS,andNmnat,”Annual Review of Neuroscience,vol.33,pp.
245–267, 2010.
[19] M. E. Vargas and B. A. Barres, “Why is Wallerian degeneration
in the CNS so slow?” Annual Review of Neuroscience, vol. 30,
pp. 153–179, 2007.
[20] S. David and S. Lacroix, “Molecular approaches to spinal cord
repair,” Annual Review of Neuroscience, vol. 26, pp. 411–440,
2003.
[21] T. Gordon, “The role of neurotrophic factors in nerve
regeneration,” Neurosurgical Focus,v o l .2 6 ,n o .2 ,a r t i c l eE 3 ,
2009.
[22] S. Walsh and R. Midha, “Practical considerations concerning
the use of stem cells for peripheral nerve repair,” Neurosurgical
Focus, vol. 26, no. 2, p. E2, 2009.
[23] G. Vrbova, N. Mehra, H. Shanmuganathan, N. Tyreman,
M. Schachner, and T. Gordon, “Chemical communication
between regenerating motor axons and Schwann cells in the
growthpathway,”EuropeanJournalofNeuroscience,vol.30,no.
3, pp. 366–375, 2009.
[24] R. Martini, M. Schachner, and T. M. Brushart, “The L2/HNK-
1 carbohydrate is preferentially expressed by previously motor
axon-associated Schwann cells in reinnervated peripheral
nerves,” The Journal of Neuroscience, vol. 14, no. 11, pp. 7180–
7191, 1994.
[25] S. Goethals, E. Ydens, V. Timmerman, and S. Janssens, “Toll-
likereceptorexpressionintheperipheralnerve,”GLIA,vol.58,
no. 14, pp. 1701–1709, 2010.
[26] G. Stoll, S. Jander, and R. R. Myers, “Degeneration and
regeneration of the peripheral nervous system: from Augustus
Waller’s observations to neuroinﬂammation,” Journal of the
Peripheral Nervous System, vol. 7, no. 1, pp. 13–27, 2002.
[ 2 7 ]E .B .G e o r g e ,J .D .G l a s s ,a n dJ .W .G r i ﬃn, “Axotomy-induced
axonal degeneration is mediated by calcium inﬂux through
ion-speciﬁc channels,” Journal of Neuroscience, vol. 15, no. 10,
pp. 6445–6452, 1995.
[28] A. D. Gaudet, P. G. Popovich, and M. S. Ramer, “Wallerian
degeneration: gaining perspective on inﬂammatory events
after peripheral nerve injury,” Journal of Neuroinﬂammation,
vol. 8, article 110, 2011.
[29] T. Gordon, N. Tyreman, and M. A. Raji, “The basis for
diminished functional recovery after delayed peripheral nerve
repair,” Journal of Neuroscience, vol. 31, no. 14, pp. 5325–5334,
2011.
[30] L. A. Pﬁster, M. Papalo¨ ızos, H. P. Merkle, and B. Gander,
“Nerve conduits and growth factor delivery in peripheral
nerve repair,” Journal of the Peripheral Nervous System, vol. 12,
no. 2, pp. 65–82, 2007.
[ 3 1 ]J .H u ,Q .T .Z h u ,X .L .L i u ,Y .B .X u ,a n dJ .K .Z h u ,“ R e p a i r
of extended peripheral nerve lesions in rhesus monkeys using
acellular allogenic nerve grafts implanted with autologous
mesenchymal stem cells,” Experimental Neurology, vol. 204,
no. 2, pp. 658–666, 2007.
[32] M. ˚ Aberg, C. Ljungberg, E. Edin et al., “Clinical evaluation
of a resorbable wrap-around implant as an alternative to
nerve repair: a prospective, assessor-blinded, randomised
clinical study of sensory, motor and functional recovery after
peripheral nerve repair,” Journal of Plastic, Reconstructive and
Aesthetic Surgery, vol. 62, no. 11, pp. 1503–1509, 2009.The Scientiﬁc World Journal 9
[33] I. A. McKenzie, J. Biernaskie, J. G. Toma, R. Midha, and
F. D. Miller, “Skin-derived precursors generate myelinating
Schwann cells for the injured and dysmyelinated nervous
system,” Journal of Neuroscience, vol. 26, no. 24, pp. 6651–
6660, 2006.
[34] E. Udina, F. J. Rodr´ ıguez, E. Verd´ u, M. Espejo, B. G. Gold,
andX.Navarro,“FK506enhancesregenerationofaxonsacross
long peripheral nerve gaps repaired with collagen guides
seeded with allogeneic Schwann cells,” GLIA,v o l .4 7 ,n o .2 ,
pp. 120–129, 2004.
[35] A. J. Reid, M. Sun, M. Wiberg, S. Downes, G. Terenghi,
and P. J. Kingham, “Nerve repair with adipose-derived stem
cells protects dorsal root ganglia neurons from apoptosis,”
Neuroscience, vol. 199, pp. 515–522, 2011.
[36] P. G. di Summa, P. J. Kingham, W. Raﬀoul, M. Wiberg, G.
Terenghi, and D. F. Kalbermatten, “Adipose-derived stem cells
enhance peripheral nerve regeneration,” Journal of Plastic,
Reconstructive and Aesthetic Surgery, vol. 63, no. 9, pp. 1544–
1552, 2010.
[37] G. R. Evans, K. Brandt, S. Katz et al., “Bioactive poly(L-lactic
acid) conduits seeded with Schwann cells for peripheral nerve
regeneration,” Biomaterials, vol. 23, no. 3, pp. 841–848, 2002.
[38] M. Koshimune, K. Takamatsu, H. Nakatsuka, K. Inui, Y.
Yamano, and Y. Ikada, “Creating bioabsorbable Schwann
cell coated conduits through tissue engineering,” Bio-Medical
Materials and Engineering, vol. 13, no. 3, pp. 223–229, 2003.
[39] A. Ladak, J. Olson, E. E. Tredget, and T. Gordon, “Diﬀeren-
tiation of mesenchymal stem cells to support peripheral nerve
regenerationinaratmodel,”ExperimentalNeurology,vol.228,
no. 2, pp. 242–252, 2011.
[40] L. E. Kokai, A. M. Ghaznavi, and K. G. Marra, “Incorporation
of double-walled microspheres into polymer nerve guides for
the sustained delivery of glial cell line-derived neurotrophic
factor,” Biomaterials, vol. 31, no. 8, pp. 2313–2322, 2010.
[41] M.Dezawa,I.Takahashi,M.Esaki,M.Takano,andH.Sawada,
“Sciatic nerve regeneration in rats induced by transplantation
of in vitro diﬀerentiated bone-marrow stromal cells,” Euro-
pean Journal of Neuroscience, vol. 14, no. 11, pp. 1771–1776,
2001.
[42] C. Marchesi, M. Pluderi, F. Colleoni et al., “Skin-derived stem
cells transplanted into resorbable guides provide functional
nerve regeneration after sciatic nerve resection,” GLIA, vol. 55,
no. 4, pp. 425–438, 2007.
[43] A. D. Ansselin, T. Fink, and D. F. Davey, “Peripheral nerve
regeneration through nerve guides seeded with adult Schwann
cells,” Neuropathology and Applied Neurobiology, vol. 23, no. 5,
pp. 387–398, 1997.
[44] F.Sun,K.Zhou,W.-J.Mi,andJ.-H.Qiu,“Repairoffacialnerve
defects with decellularized artery allografts containing autolo-
gous adipose-derived stem cells in a rat model,” Neuroscience
Letters, vol. 499, no. 2, pp. 104–108, 2011.
[45] B. Cheng and Z. Chen, “Fabricating autologous tissue to
engineer artiﬁcial nerve,” Microsurgery, vol. 22, no. 4, pp. 133–
137, 2002.
[46] F. Zhang, B. Blain, J. Beck et al., “Autogenous venous graft
with one-stage prepared Schwann cells as a conduit for repair
of long segmental nerve defects,” Journal of Reconstructive
Microsurgery, vol. 18, no. 4, pp. 295–300, 2002.
[47] S.Wakao,T.Hayashi,M.Kitadaetal.,“Long-termobservation
of auto-cell transplantation in non-human primate reveals
safety and eﬃciency of bone marrow stromal cell-derived
Schwann cells in peripheral nerve regeneration,” Experimental
Neurology, vol. 223, no. 2, pp. 537–547, 2010.
[48] I. K. Fox and S. E. MacKinnon, “Adult peripheral nerve
disorders: nerve entrapment, repair, transfer, and brachial
plexus disorders,” Plastic and Reconstructive Surgery, vol. 127,
no. 5, pp. 105e–118e, 2011.
[49] B. Schlosshauer, L. Dreesmann, H. E. Schaller, and N. Sinis,
“Synthetic nerve guide implants in humans: a comprehensive
survey,” Neurosurgery, vol. 59, no. 4, pp. 740–747, 2006.
[50] Y. T. Kim, V. K. Haftel, S. Kumar, and R. V. Bellamkonda, “The
role of aligned polymer ﬁber-based constructs in the bridging
of long peripheral nerve gaps,” Biomaterials, vol. 29, no. 21,
pp. 3117–3127, 2008.
[51] J. J. Liu, C. Y. Wang, J. G. Wang, H. J. Ruan, and C. Y. Fan,
“Peripheral nerve regeneration using composite poly(lactic
acid-caprolactone)/nerve growth factor conduits prepared
by coaxial electrospinning,” Journal of Biomedical Materials
Research A, vol. 96, no. 1, pp. 13–20, 2011.
[ 5 2 ]C .R a d t k e ,A .A .A i z e r ,S .K .A g u l i a n ,K .L .L a n k f o r d ,P .
M. Vogt, and J. D. Kocsis, “Transplantation of olfactory
ensheathing cells enhances peripheral nerve regeneration after
microsurgical nerve repair,” Brain Research, vol. 1254, pp. 10–
17, 2009.
[53] E. Verd´ u, X. Navarro, G. Gudi˜ no-Cabrera et al., “Olfactory
bulb ensheathing cells enhance peripheral nerve regenera-
tion,” NeuroReport, vol. 10, no. 5, pp. 1097–1101, 1999.
[54] H. You, L. Wei, Y. Liu et al., “Olfactory ensheathing cells
enhance Schwann cell-mediated anatomical and functional
repair after sciatic nerve injury in adult rats,” Experimental
Neurology, vol. 229, no. 1, pp. 158–167, 2011.
[55] A.A.Lavdas,I.Franceschini,M.Dubois-Dalcq,andR.Matsas,
“Schwann cells genetically engineered to express PSA show
enhanced migratory potential without impairment of their
myelinating ability in vitro,” GLIA, vol. 53, no. 8, pp. 868–878,
2006.
[56] F. Papastefanaki, J. Chen, A. A. Lavdas, D. Thomaidou, M.
Schachner, andR.Matsas,“GraftsofSchwann cellsengineered
to express PSA-NCAM promote functional recovery after
spinalcordinjury,”Brain,vol.130,no.8,pp.2159–2174,2007.
[57] D. Siu, “A new way of targeting to treat nerve injury,”
International Journal of Neuroscience, vol. 120, no. 1, pp. 1–10,
2010.
[58] Y. Zhang, J. Yeh, P. M. Richardson, and X. Bo, “Cell adhesion
molecules of the immunoglobulin superfamily in axonal
regeneration and neural repair,” Restorative Neurology and
Neuroscience, vol. 26, no. 2-3, pp. 81–96, 2008.
[59] N. M. Le Douarin and E. Dupin, “Multipotentiality of the
neural crest,” Current Opinion in Genetics and Development,
vol. 13, no. 5, pp. 529–536, 2003.
[60] A. Woodhoo and L. Sommer, “Development of the Schwann
cell lineage: from the neural crest to the myelinated nerve,”
Glia, vol. 56, no. 14, pp. 1481–1490, 2008.
[61] C. V. Borlongan, “Remyelinating the transected peripheral
nervebyfabricatedSchwanncellsderivedfrombonemarrow,”
Experimental Neurology, vol. 225, no. 2, pp. 243–245, 2010.
[ 6 2 ]I .D .D u n c a n ,A .J .A g u a y o ,R .P .B u n g e ,a n dP .M .W o o d ,
“Transplantation of rat Schwann cells grown in tissue culture
into the mouse spinal cord,” Journal of the Neurological
Sciences, vol. 49, no. 2, pp. 241–252, 1981.
[ 6 3 ]B .H o o d ,H .B .L e v e n e ,a n dA .D .L e v i ,“ T r a n s p l a n t a t i o n
of autologous Schwann cells for the repair of segmental
peripheral nerve defects,” Neurosurgical Focus, vol. 26, no. 2,
p. E4, 2009.
[64] A. Niapour, F. Karamali, K. Karbalaie et al., “Novel method
to obtain highly enriched cultures of adult rat Schwann cells,”
Biotechnology Letters, vol. 32, no. 6, pp. 781–786, 2010.10 The Scientiﬁc World Journal
[65] K. Le Blanc and O. Ringd´ en, “Immunomodulation by mes-
enchymal stem cells and clinical experience,” Journal of
Internal Medicine, vol. 262, no. 5, pp. 509–525, 2007.
[66] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage
potential of adult human mesenchymal stem cells,” Science,
vol. 284, no. 5411, pp. 143–147, 1999.
[67] G. Keilhoﬀ, K. Langnaese, G. Wolf, and H. Fansa, “Inhibiting
eﬀect of minocycline on the regeneration of peripheral
nerves,”DevelopmentalNeurobiology,vol.67,no.10,pp.1382–
1395, 2007.
[68] M. Tohill and G. Terenghi, “Stem-cell plasticity and therapy
for injuries of the peripheral nervous system,” Biotechnology
and Applied Biochemistry, vol. 40, no. 1, pp. 17–24, 2004.
[69] C. E. Wong, C. Paratore, M. T. Dours-Zimmermann et al.,
“Neuralcrest-derivedcellswithstemcellfeaturescanbetraced
back to multiple lineages in the adult skin,” Journal of Cell
Biology, vol. 175, no. 6, pp. 1005–1015, 2006.
[70] Y. Amoh, L. Li, M. Yang et al., “Hair follicle-derived blood
vessels vascularize tumors in skin and are inhibited by
doxorubicin,” Cancer Research, vol. 65, no. 6, pp. 2337–2343,
2005.
[71] J. Biernaskie, J. S. Sparling, J. Liu et al., “Skin-derived pre-
cursors generate myelinating Schwann cells that promote
remyelination and functional recovery after contusion spinal
cord injury,” Journal of Neuroscience, vol. 27, no. 36, pp. 9545–
9559, 2007.
[72] P. J. Kingham, D. F. Kalbermatten, D. Mahay, S. J. Armstrong,
M. Wiberg, and G. Terenghi, “Adipose-derived stem cells
diﬀerentiate into a Schwann cell phenotype and promote
neurite outgrowth in vitro,” Experimental Neurology, vol. 207,
no. 2, pp. 267–274, 2007.
[73] A. Niapour, F. Karamali, S. Nemati et al., “Co-transplantation
ofhumanembryonic stemcell-derived neuralprogenitors and
schwann cells in a rat spinal cord contusion injury model
elicits a distinct neurogenesis and functional recovery,” Cell
Transplantation. In press.
[74] C.E.Hill,L.D.Moon,P.M.Wood,andM.B.Bunge,“Labeled
Schwann cell transplantation: cell loss, host Schwann cell
replacement, and strategies to enhance survival,” GLIA, vol.
53, no. 3, pp. 338–343, 2006.
[75] F. Sun, K. Zhou, W.-J. Mi, and J.-H. Qiu, “Combined use
of decellularized allogeneic artery conduits with autologous
transdiﬀerentiated adipose-derived stem cells for facial nerve
regeneration in rats,” Biomaterials, vol. 32, no. 32, pp. 8118–
8128, 2011.
[76] E. E. Sabelman and V. R. Hentz, “Clinical Trial of Peripheral
Nerve Graft,” ClinicalTrials.gov, 1999.
[77] AxoGen, Inc., “Study of Nerve Reconstruction using AVANCE
in Subjects Who Undergo Robotic Assisted Prostatectomy for
Treatment of Prostate Cancer,” ClinicalTrials.gov, 2011.
[78] AxoGen, Inc., “Avance Nerve Graft: The Natural Connection,”
2011, http://www.Axogeninc.com.
[79] AxoGen, Inc., “Study of Nerve Reconstruction using AVANCE
in Subjects Who Undergo Robotic Assisted Prostatectomy for
Treatment of Prostate Cancer,” ClinicalTrials.gov, 2011.
[ 8 0 ]A .B l e s c h ,H .S .U y ,R .J .G r i l l ,J .G .C h e n g ,P .H .P a t t e r s o n ,
and M. H. Tuszynski, “Leukemia inhibitory factor augments
neurotrophin expression and corticospinal axon growth after
adult CNS injury,” Journal of Neuroscience, vol. 19, no. 9, pp.
3556–3566, 1999.
[81] A. A. Lavdas, F. Papastefanaki, D. Thomaidou, and R. Matsas,
“Schwann celltransplantationforCNSrepair,”CurrentMedic-
inal Chemistry, vol. 15, no. 2, pp. 151–160, 2008.
[82] K. Tan, E. Lessieur, A. Cutler et al., “Impaired function of
circulating CD34+ CD45− cells in patients with proliferative
diabetic retinopathy,” Experimental Eye Research, vol. 91, no.
2, pp. 229–237, 2010.
[83] W. Wagner, S. Bork, P. Horn et al., “Aging and replicative
senescence have related eﬀects on human stem and progenitor
cells,” Plos ONE, vol. 4, no. 6, Article ID e5846, 2009.
[84] J. Doorn, G. Moll, K. Le Blanc, C. van Blitterswijk, and J.
De Boer, “Therapeutic applications of mesenchymal stromal
cells: paracrine eﬀects and potential improvements,” Tissue
Engineering B, vol. 18, pp. 101–115, 2012.
[85] G. Moll, R. Jitschin, L. von Bahr et al., “Mesenchymal stromal
cells engage complement and complement receptor bearing
innate eﬀector cells to modulate immune responses,” Plos
ONE, vol. 6, no. 7, Article ID e21703, 2011.